GeneticICD-10: D66Hemophilia A affects approximately 1 in 5,000 male births

Hemophilia

Also known as: Bleeding Disorder, Hemophilia A, Hemophilia B, Christmas Disease

Hemophilia is a rare inherited bleeding disorder in which the blood does not clot properly due to a deficiency or absence of specific clotting factors, primarily factor VIII (hemophilia A) or factor IX (hemophilia B). People with hemophilia experience prolonged bleeding after injuries, surgery, or dental procedures, and severe cases can cause spontaneous bleeding into joints, muscles, and internal organs. Although hemophilia primarily affects males due to its X-linked inheritance pattern, females can be carriers and occasionally experience mild symptoms.

Last updated November 10, 2026

Understanding Hemophilia

Hemophilia is an inherited deficiency of one clotting factor: factor VIII in hemophilia A, which accounts for about 80 percent of cases, and factor IX in hemophilia B. About 33,000 males in the United States live with it, and the CDC's prevalence estimate of roughly 12 per 100,000 males for hemophilia A and 4 per 100,000 for hemophilia B is consistent with the often-quoted figure of 1 in 5,000 male births. Because both genes sit on the X chromosome, the full disorder almost always appears in boys, but about a quarter to a third of carrier women have factor levels low enough to bleed heavily with periods, childbirth and surgery, and are now formally classified as having mild hemophilia when their level is under 40 percent. Roughly one in three affected boys has no family history because the mutation is new. Severity is set by the baseline factor level: severe is under 1 percent of normal, moderate 1 to 5 percent, and mild 5 to 40 percent, and that number predicts the pattern of bleeding better than anything else.

Factors VIII and IX work together to amplify the clotting cascade on the surface of activated platelets, so without one of them a platelet plug forms but the fibrin mesh that should lock it in place never builds. The result is not faster bleeding but bleeding that will not stop, often starting hours after the injury, and bleeding into closed spaces that a normal person would never notice. In severe hemophilia, joints bleed spontaneously 20 to 30 times a year without treatment, most often knees, elbows and ankles; blood irritates the synovium, iron deposits inflame it, and repeated bleeds into the same target joint destroy cartilage within a decade, which is why men who grew up before prophylaxis commonly needed joint replacements in their 30s. Bleeding into the brain is the leading cause of death from the disease itself, with a lifetime risk of 2 to 8 percent in severe cases and the highest danger in the first year of life. Mild hemophilia may go undiagnosed until a tooth extraction or an operation produces bleeding that will not settle.

Modern care has changed the disease more in 10 years than in the previous 50. The World Federation of Hemophilia 2020 guidelines recommend prophylaxis, regular treatment to prevent bleeds rather than waiting for them, for everyone with severe disease from before age 3; in the landmark 2007 Joint Outcome Study, boys on prophylaxis had 85 percent less joint damage on MRI at age 6 than boys treated on demand. Extended-half-life factors have cut infusions to once or twice a week, and emicizumab, an injected antibody that mimics factor VIII, reduced treated bleeds by 87 to 97 percent in the HAVEN trials with dosing as infrequent as every 4 weeks, with or without inhibitors. Gene therapy is now a real option for adults: valoctocogene roxaparvovec for hemophilia A, FDA-approved in 2023, lifted factor VIII into the mild or normal range in most recipients, though levels fall by a third or more over the first few years; etranacogene dezaparvovec for hemophilia B, approved in 2022, produced factor IX levels around 35 to 40 percent that have held for over 3 years and cut annual bleeds by about 64 percent. Both need antibody screening, liver monitoring and sometimes steroids. About 25 to 30 percent of people with severe hemophilia A develop inhibitors, antibodies that neutralize infused factor, usually within the first 50 exposures; they are managed with immune tolerance induction, bypassing agents and emicizumab.

There is no supplement, herb or diet that raises factor VIII or IX or reduces bleeding, and this is worth stating flatly because the question is asked constantly. Vitamin K does nothing for hemophilia: the body uses it to finish building factor IX, but in hemophilia B the gene for factor IX is faulty, so more vitamin K cannot help, and factor VIII is not vitamin K dependent at all. The 'natural' interventions that genuinely have evidence are physical. Regular, supervised exercise and physiotherapy strengthen the muscles around target joints, improve proprioception and reduce bleed frequency, and the WFH guidelines recommend them for everyone. Dental care with a hygienist every 6 months prevents gum disease, which is a common and avoidable source of bleeding, and tranexamic acid mouthwash or tablets prescribed around dental work cut post-extraction bleeding by more than half. Correcting measured deficiencies matters: iron if ferritin is low after bleeds, vitamin D if low because low bone density is twice as common in hemophilia. Several popular supplements actively increase bleeding risk and should be avoided: fish oil above about 1 g a day, vitamin E above 400 IU, ginkgo, garlic extracts, ginger in supplement doses, turmeric or curcumin capsules, feverfew, dong quai and high-dose willow bark, which contains salicylate.

The most common and most dangerous mistake is treating a head injury like a normal person would, by watching and waiting. In hemophilia, a bang to the head, a fall from standing in an older adult, or an unexplained severe headache, vomiting or drowsiness means infusing factor (or calling the treatment center about bypassing agents if there are inhibitors) first and getting a CT scan second, with no waiting for symptoms to develop; bleeding in the skull can take hours to declare itself and is treatable only if treated early. The second mistake is reaching for aspirin, ibuprofen, naproxen or any NSAID for pain, including the ones hidden in cold remedies and the salicylate in Pepto-Bismol: they block platelet function and turn a manageable bleed into a serious one. Acetaminophen is the safe choice for pain, and a COX-2 selective drug such as celecoxib is sometimes used under specialist advice. The third mistake is skipping prophylaxis doses in a good spell: joint damage from breakthrough bleeds is cumulative and does not reverse.

At a Glance

Common symptoms
Excessive bleeding from cuts, injuries, or surgical procedures, Spontaneous bleeding into joints (hemarthrosis) causing pain and swelling, Unexplained large or deep bruises
Main treatments
Replacement therapy with clotting factor concentrates (recombinant or plasma-derived), Emicizumab (Hemlibra) prophylaxis for hemophilia A with or without inhibitors, Desmopressin (DDAVP) for mild hemophilia A to stimulate factor VIII release
Category
Genetic · Hemophilia A affects approximately 1 in 5,000 male births
See a doctor if
Bleeding does not stop after appropriate first aid measures

Symptoms

Excessive bleeding from cuts, injuries, or surgical procedures
Spontaneous bleeding into joints (hemarthrosis) causing pain and swelling
Unexplained large or deep bruises
Prolonged bleeding after dental work or tooth extractions
Blood in the urine (hematuria) or stool
Nosebleeds that are difficult to stop
Bleeding into muscles causing compartment syndrome
Intracranial hemorrhage in severe cases (medical emergency)

Causes

  • X-linked recessive genetic mutation affecting clotting factor genes
  • Deficiency of clotting factor VIII (hemophilia A, most common)
  • Deficiency of clotting factor IX (hemophilia B, also known as Christmas disease)
  • Spontaneous gene mutations (approximately 30% of cases have no family history)

Risk Factors

  • Family history of hemophilia
  • Male sex (X-linked recessive inheritance)
  • Being born to a female carrier of the hemophilia gene
  • Having a spontaneous new mutation in the clotting factor gene

Diagnosis

  • Complete blood count (CBC) and coagulation studies (PT, PTT)
  • Clotting factor assays to measure levels of factor VIII or IX
  • Genetic testing to identify specific gene mutations
  • Family history assessment and carrier testing for at-risk females

Treatment

  • Replacement therapy with clotting factor concentrates (recombinant or plasma-derived)
  • Emicizumab (Hemlibra) prophylaxis for hemophilia A with or without inhibitors
  • Desmopressin (DDAVP) for mild hemophilia A to stimulate factor VIII release
  • Gene therapy (valoctocogene roxaparvovec) as an emerging treatment option
  • Physical therapy to maintain joint health and mobility
  • Antifibrinolytic medications (tranexamic acid) for dental and mucosal bleeding

Natural remedies for hemophilia: what the evidence says

Ranked by the strength of human evidence for hemophilia specifically. These sit alongside medical care, not in place of it.

  1. Vitamin D

    Preliminary evidence

    Low bone density affects roughly two in three adults with severe hemophilia in pooled studies, driven by reduced loading of painful joints, and vitamin D deficiency is found in 50 to 80 percent of patients in treatment-center surveys. No trial shows vitamin D reduces bleeding; its role is to protect bone in people who already fracture more easily and heal more slowly. Guidelines recommend checking a 25-hydroxyvitamin D level and correcting a deficiency rather than supplementing blindly.

    Studied dose
    1,000 to 2,000 IU vitamin D3 daily if the blood level is below 30 ng/mL, with dietary calcium of about 1,000 to 1,200 mg a day; higher repletion doses only under supervision.
    Cautions
    Doses above 4,000 IU daily without monitoring can raise calcium; interacts with thiazide diuretics. Do not expect it to change factor levels or bleed frequency.
  2. Iron

    Preliminary evidence

    Repeated joint, muscle, nose and menstrual bleeding drains iron stores, and iron-deficiency anemia is common in people with hemophilia and in carriers with heavy periods. Iron replacement corrects the anemia and its fatigue in a matter of weeks to months, but it treats the consequence of bleeding, not the bleeding itself. The decision should rest on a ferritin and complete blood count, not on symptoms alone.

    Studied dose
    If ferritin is low, 40 to 65 mg elemental iron once daily or every other day with vitamin C, recheck ferritin after 8 to 12 weeks; intravenous iron for people who cannot tolerate or absorb tablets.
    Cautions
    Causes constipation, dark stools and nausea; dark stools can mask the black, tarry stool of a gastrointestinal bleed, so tell your treatment center you are taking it. Separate from levothyroxine, tetracyclines and quinolones by 2 to 4 hours. Never take iron without a confirmed deficiency.

What matters day to day

  • Exercise regularly in low-impact activities such as swimming, cycling and strength training, with physiotherapist guidance: a 2022 systematic review found structured exercise programs improved joint range, muscle strength and pain in hemophilia without increasing bleeds, and stronger quadriceps measurably protect the knee.
  • Keep acetaminophen, not ibuprofen or aspirin, as the household pain reliever, and read labels on cold and flu products: a single dose of aspirin impairs platelets for 7 to 10 days, and NSAIDs multiply the bleeding risk of a clotting factor deficiency.
  • See a dental hygienist every 6 months and brush with a soft brush twice a day: gum disease is one of the most common sources of bleeding in hemophilia, and telling the dentist in advance lets them arrange tranexamic acid cover for extractions and deep cleaning.
  • Carry a treatment card or medical alert bracelet naming your type, severity, inhibitor status and treatment center phone number: emergency clinicians will otherwise follow standard protocols that delay factor replacement.
  • Treat any bleed early: the WFH rule is to infuse within 2 hours of the first tingling or stiffness in a joint, because a bleed treated at that stage needs one dose where a swollen joint needs several and leaves lasting damage.
  • Keep a healthy weight: every extra kilogram loads damaged knees and ankles, obesity roughly doubles the chance of developing a target joint, and higher body weight raises the dose, and the cost, of every factor infusion.

Prevention

  • No prevention for the genetic condition itself
  • Genetic counseling and carrier testing for families with hemophilia history
  • Prophylactic clotting factor infusions to prevent spontaneous bleeding episodes
  • Avoiding contact sports and activities with high injury risk
  • Wearing a medical alert bracelet to inform emergency responders

When to See a Doctor

  • Bleeding does not stop after appropriate first aid measures
  • You experience sudden joint swelling, warmth, or pain suggestive of joint bleeding
  • You have a head injury or develop a severe headache, neck stiffness, or vomiting
  • You notice blood in your urine, stool, or have unusual bruising patterns

Frequently Asked Questions

References

  1. Srivastava A, Santagostino E, Dougall A, et al.. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia (2020)
  2. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al.. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. New England Journal of Medicine (2007)
  3. Mahlangu J, Oldenburg J, Paz-Priel I, et al.. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. New England Journal of Medicine (2018)
  4. Ozelo MC, Mahlangu J, Pasi KJ, et al.. Valoctocogene roxaparvovec gene therapy for hemophilia A. New England Journal of Medicine (2022)
  5. Pipe SW, Leebeek FWG, Recht M, et al.. Gene therapy with etranacogene dezaparvovec for hemophilia B. New England Journal of Medicine (2023)
  6. Blanchette VS, Key NS, Ljung LR, et al.. Definitions in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis (2014)
  7. Paschou SA, Anagnostis P, Karras S, et al.. Bone mineral density in patients with haemophilia: a systematic review and meta-analysis. Thrombosis and Haemostasis (2014)
  8. Centers for Disease Control and Prevention. Data and Statistics on Hemophilia (2024)
  9. National Heart, Lung, and Blood Institute. Hemophilia (2022)

Related Conditions

Lab tests that relate to hemophilia

Have questions about Hemophilia?

Ask Mother Nature AI for personalized, evidence-based guidance.

Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.